Articles

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA;Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Cancer Research and Biostatistics, Seattle, WA, USA
Cancer Research and Biostatistics, Seattle, WA, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Cancer Research and Biostatistics, Seattle, WA, USA
Celgene Corporation, Summit, NJ, USA
Celgene Institute for Translational Research Europe, Seville, Spain
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Translational Genomics Research Institute, Phoenix, AZ, USA
Multiple Myeloma Research Foundation, Norwalk, CT, USA
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Celgene Corporation, Summit, NJ, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA;Division of Hematology Oncology, Indiana Univeristy, Indianapolis, IN, USA
Vol. 105 No. 4 (2020): April, 2020 https://doi.org/10.3324/haematol.2019.217927